DR REDDYS LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of DR REDDYS LABORATORIES have increased by 13.11% YoY .
The Earnings Per Share (EPS) of DR REDDYS LABORATORIES has increased by 106.27 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
DR REDDYS LABORATORIES Last 5 Annual Financial Results
[BOM: 500124|NSE : DRREDDY]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹21,545 Cr | ₹19,048 Cr | ₹17,517 Cr | ₹15,448 Cr | ₹14,281 Cr |
| Expenses | ₹17,778 Cr | ₹15,178 Cr | ₹15,047 Cr | ₹12,270 Cr | ₹11,930 Cr |
| Operating Profit (Excl OI) | ₹3,767 Cr | ₹3,870 Cr | ₹2,470 Cr | ₹3,178 Cr | ₹2,351 Cr |
| Other Income | ₹485 Cr | ₹291 Cr | ₹621 Cr | ₹338 Cr | ₹155 Cr |
| Interest | ₹96 Cr | ₹97 Cr | ₹98 Cr | ₹89 Cr | ₹79 Cr |
| Depreciation | ₹1,165 Cr | ₹1,229 Cr | ₹1,163 Cr | ₹1,135 Cr | ₹1,077 Cr |
| Profit Before Tax | ₹3,061 Cr | ₹2,884 Cr | ₹1,886 Cr | ₹2,336 Cr | ₹1,350 Cr |
| Profit After Tax | ₹2,183 Cr | ₹1,952 Cr | ₹2,026 Cr | ₹1,950 Cr | ₹912 Cr |
| Consolidated Net Profit | ₹2,183 Cr | ₹1,952 Cr | ₹2,026 Cr | ₹1,950 Cr | ₹947 Cr |
| Earnings Per Share (Rs) | ₹270.55 | ₹131.16 | ₹117.28 | ₹121.90 | ₹117.47 |
| PAT Margin (%) | 18.27 | 10.13 | 10.25 | 11.57 | 12.62 |
| ROE(%) | 21.36 | 11.93 | 11.82 | 13.76 | 14.75 |
| ROCE(%) | 26.22 | 14.59 | 15.49 | 11.12 | 13.66 |
| Total Debt/Equity(x) | 0.06 | 0.18 | 0.17 | 0.14 | 0.28 |
Key Financials |
||
| Market Cap | : | ₹ 96,990.9 Cr |
| Revenue (TTM) | : | ₹ 28,011.1 Cr |
| Net Profit(TTM) | : | ₹ 5,563.2 Cr |
| EPS (TTM) | : | ₹ 333.5 |
| P/E (TTM) | : | 17.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
| CIPLA | 3.5% | 4.2% | 51.8% |
| ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
| DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
| MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
| TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
| LUPIN | 1.5% | 4.2% | 109.2% |
| AUROBINDO PHARMA | 3.1% | 7.9% | 81.3% |
DR REDDYS LABORATORIES Revenues
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 13.11 % |
| 5 Yr CAGR | 10.83 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹21,545 Cr | 13.11 | |
| Mar2022 | ₹19,048 Cr | 8.74 | |
| Mar2021 | ₹17,517 Cr | 13.39 | |
| Mar2020 | ₹15,448 Cr | 8.17 | |
| Mar2019 | ₹14,281 Cr | - | |
DR REDDYS LABORATORIES Operating Profit
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | -2.65 % |
| 5 Yr CAGR | 12.51 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,767 Cr | -2.65 | |
| Mar2022 | ₹3,870 Cr | 56.65 | |
| Mar2021 | ₹2,470 Cr | -22.27 | |
| Mar2020 | ₹3,178 Cr | 35.17 | |
| Mar2019 | ₹2,351 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -13.93 % |
| 5 Yr CAGR | 1.53 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 17.49% | -13.93 | |
| Mar2022 | 20.32% | 44.11 | |
| Mar2021 | 14.1% | -31.45 | |
| Mar2020 | 20.57% | 24.97 | |
| Mar2019 | 16.46% | - | |
DR REDDYS LABORATORIES Profit After Tax
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 11.83 % |
| 5 Yr CAGR | 23.22 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹2,183 Cr | 11.83 | |
| Mar2022 | ₹1,952 Cr | -3.67 | |
| Mar2021 | ₹2,026 Cr | 3.90 | |
| Mar2020 | ₹1,950 Cr | 105.96 | |
| Mar2019 | ₹947 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 80.36 % |
| 5 Yr CAGR | 9.69 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 18.27 % | 80.36 | |
| Mar2022 | 10.13 % | -1.17 | |
| Mar2021 | 10.25 % | -11.41 | |
| Mar2020 | 11.57 % | -8.32 | |
| Mar2019 | 12.62 % | - | |
DR REDDYS LABORATORIES Earnings Per Share (EPS)
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 106.27 % |
| 5 Yr CAGR | 23.19 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹271 | 106.27 | |
| Mar2022 | ₹131 | 11.83 | |
| Mar2021 | ₹117 | -3.79 | |
| Mar2020 | ₹122 | 3.77 | |
| Mar2019 | ₹117 | - | |
DR REDDYS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 79.71 % |
| 5 Yr CAGR | 17.71 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 26.22% | 79.71 | |
| Mar2022 | 14.59% | -5.81 | |
| Mar2021 | 15.49% | 39.30 | |
| Mar2020 | 11.12% | -18.59 | |
| Mar2019 | 13.66% | - | |
DR REDDYS LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹5,814.8 |
| Current MarketCap | : | ₹ 96,990.9 Cr |
| Updated EOD on | : | May 18,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR REDDYS LABORATORIES | -1% |
-2.4% |
28.4% |
| SENSEX | 1.7% |
1.5% |
18.7% |
DR REDDYS LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE DIVIDEND STABILITY | 3.4% | 3.9% | 55% |
| S&P BSE ALLCAP | 3.2% | 3.6% | 36.9% |
| S&P BSE 500 | 3% | 3.4% | 35% |
| MFG | 2.8% | 2.2% | 39.3% |
| S&P BSE 250 LARGEMIDCAP | 2.7% | 3.3% | 33% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY200 MOMENTUM 30 INDEX | 5.1% | 9.3% | 71.6% |
| NIFTY 100 ALPHA 30 | 4.6% | 6.6% | 69.3% |
| NIFTY500 MULTICAP 50:25:25 | 3.8% | 4.2% | 44.5% |
| NIFTY ALPHA QTY VAL LOW-VOL 30 | 3.5% | 6.5% | 61.7% |
| NIFTY LARGE MIDCAP 250 | 3.5% | 4.4% | 42.9% |
You may also like the below Video Courses
FAQ about DR REDDYS LABORATORIES Financials
How the annual revenues of DR REDDYS LABORATORIES have changed ?
The Revenues of DR REDDYS LABORATORIES have increased by 13.11% YoY .
How the Earnings per Share (EPS) of DR REDDYS LABORATORIES have changed?
The Earnings Per Share (EPS) of DR REDDYS LABORATORIES has increased by 106.27 % YoY .
Check out Intrinsic Value of Peers of DR REDDYS LABORATORIES
Compare Stock Analytics of Peers of DR REDDYS LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
